Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Community strengths in addressing opioid use in Northeastern Ontario

Community strengths in addressing opioid use in Northeastern Ontario The number of opioid-related deaths in Ontario is rising, and remote First Nations communities face unique challenges in providing treatment for opioid use disorder. Geographic barriers and resource shortages limit access to opioid agonist therapy, such as buprenorphine or methadone. However, attempts to rapidly expand access have the potential to overlook community consultation. Our experience in Moose Factory, Ontario, offers insight into the ethical questions and challenges that can arise when implementing opioid agonist therapy in Northern Ontario and provides an example of how a community working group can strengthen relationships and create a culturally relevant program. We call on medical regulators and the provincial and federal governments to invest in community-based opioid dependence treatment programs that incorporate cultural and land-based healing strategies and draw on First Nations teachings. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Canadian Journal of Public Health Springer Journals

Community strengths in addressing opioid use in Northeastern Ontario

Download PDF
4 pages

Loading next page...
 
/lp/springer_journal/community-strengths-in-addressing-opioid-use-in-northeastern-ontario-XeLJ35ja5y
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Canadian Public Health Association
Subject
Medicine & Public Health; Public Health
ISSN
0008-4263
eISSN
1920-7476
DOI
10.17269/s41997-018-0055-4
Publisher site
See Article on Publisher Site

Abstract

The number of opioid-related deaths in Ontario is rising, and remote First Nations communities face unique challenges in providing treatment for opioid use disorder. Geographic barriers and resource shortages limit access to opioid agonist therapy, such as buprenorphine or methadone. However, attempts to rapidly expand access have the potential to overlook community consultation. Our experience in Moose Factory, Ontario, offers insight into the ethical questions and challenges that can arise when implementing opioid agonist therapy in Northern Ontario and provides an example of how a community working group can strengthen relationships and create a culturally relevant program. We call on medical regulators and the provincial and federal governments to invest in community-based opioid dependence treatment programs that incorporate cultural and land-based healing strategies and draw on First Nations teachings.

Journal

Canadian Journal of Public Health – Springer Journals

Published: Apr 19, 2018

References

  • The National Native Addictions Partnership Foundation Inc, and Health Canada. Honouring our strengths: a renewed framework for addressing substance use among First Nations people in Canada
  • Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone
    Dhalla, IA; Mamdani, MM; Sivilotti, ML; Kopp, A; Qureshi, O; Juurlink, DN
  • The burden of premature opioid-related mortality
    Gomes, T; Mamdani, MM; Dhalla, IA; Cornish, S; Paterson, JM; Juurlink, DN
  • Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program
    Kanate, D; Folk, D; Cirone, S; Gordon, J; Kirlew, M
  • Incidence of narcotic abuse during pregnancy in northwestern Ontario: three-year prospective cohort study
    Kelly, L; Guilfoyle, J; Dooley, J; Antone, I; Gerber-Finn, L
  • Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study
    Kimber, J; Larney, S; Hickman, M; Randall, D; Degenhardt, L
  • Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: retrospective study
    Mamakwa, S; Kahan, M; Kanate, D; Kirlew, M; Folk, D
  • Prescription drug abuse state of emergency
  • Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone?
    Srivastava, A; Kahan, M; Nader, M